BioAxone announces first patient treatment in acute spinal cord injury trial
MONTREAL, Feb. 7 /CNW Telbec/ - BioAxone Therapeutics Inc., a
biopharmaceutical company, has announced the first patient administration of
Cethrin(R) in the Phase I/IIa clinical trial for the treatment of acute spinal
cord injury. The first patient was administered Cethrin by Dr. Nicholas
Theodore, Neurosurgeon at St. Joseph's Hospital & Medical Center, Phoenix,
The Phase I/IIa clinical trial is a multinational study in which up to
48 patients with acute spinal cord injury will be administered Cethrin(R). The
study is designed to evaluate the safety and pharmacokinetics of rising doses
of Cethrin(R), following a single extra-dural administration during surgery
for acute thoracic and cervical spinal cord injury. The patients will be
recruited from about 8 sites in Canada and the US.
"This is a very important trial in the field of spinal cord injury. The
novel therapeutic agent and the innovative delivery process represent
significant milestones in our search to find better ways of treating patients
with acute spinal cord injury", said Dr. Nicholas Theodore.
"Cethrin(R) represents a unique approach for this treatment, and the
procedure we have developed minimizes risk to patients because it is
non-invasive", said Henry E. Khouri, PhD, MBA, Vice President, Clinical
Development at BioAxone. "We are pleased to have enrolled